Related Experiment Video
Updated: Jul 5, 2026
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
Published on: June 17, 2015
Rapamycin Reduces Amyloid-β Plaques and Improves Behavioral Performance in a Sex-Dependent Manner in Mouse Models of
Shihui Guo1,2, Weishan Fu1,2, Yating Wang1,2
1Department of Neurobiology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.
Background:
Alzheimer's disease (AD), the most common form of dementia, lacks effective disease-modifying treatments. Rapamycin, an mTOR inhibitor with immunomodulatory properties, may mitigate AD pathology by restoring microglial functions.
Methods:
Rapamycin was orally administered to 2-month-old 5xFAD and hAPPNL.
Results:
Rapamycin treatment reduced the cerebral Aβ plaque burden, alleviated dystrophic neurites, suppressed glial hyperactivation, and increased plaque-associated microglial density in both mouse models, with more pronounced effects in female mice. These pathological improvements were associated with attenuated deficits in hippocampal-dependent memory tasks (spontaneous alternation in the Y-maze and contextual fear conditioning tasks). Mechanistically, rapamycin enhances microglial lysosomal degradation, promotes lipid droplet clearance in BV2 cells, and increases Aβ phagocytic clearance in primary microglial cells.
Conclusions:
Our findings suggest that rapamycin reduces amyloid pathology and associated behavioral deficits in AD mice, an effect associated with enhanced microglial lysosomal activity and Aβ clearance, highlighting its therapeutic potential in AD treatment.
Insights
Rapamycin treatment reduced Alzheimer's disease (AD) pathology and improved memory in mouse models. This effect was linked to enhanced microglial function and amyloid clearance, suggesting rapamycin's therapeutic potential for AD.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a common dementia lacking effective treatments.
- Rapamycin, an mTOR inhibitor, possesses immunomodulatory effects.
- Rapamycin may improve AD by restoring microglial functions.
Purpose of the Study:
- To investigate rapamycin's therapeutic potential in Alzheimer's disease models.
- To assess rapamycin's impact on AD pathology and cognitive deficits.
Main Methods:
- Oral administration of rapamycin to 5xFAD and hAPP mice.
- Evaluation of neuropathological markers and cognitive functions.
- Mechanistic studies on microglial activity and amyloid clearance.
Main Results:
- Rapamycin reduced amyloid plaque burden, dystrophic neurites, and glial hyperactivation.
- Treatment improved memory deficits in hippocampal-dependent tasks.
- Enhanced microglial lysosomal degradation and Aβ phagocytic clearance were observed, particularly in female mice.
Conclusions:
- Rapamycin alleviates AD pathology and behavioral deficits in mouse models.
- Enhanced microglial function and amyloid clearance underlie rapamycin's therapeutic effects.
- Rapamycin shows promise as a potential treatment for Alzheimer's disease.
More Related Videos
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
